MeiraGTx Holdings (MGTX) Research & Development (2017 - 2026)
MeiraGTx Holdings (MGTX) reported Research & Development of $57.83 million for Q2 2026, up 72.7% from $33.5 million a year earlier.
Powered by 
Analysis
MeiraGTx Holdings (MGTX) Research & Development (2017 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, MeiraGTx Holdings' Research & Development came in at $154.67 million, up 32.8% year-over-year; for FY2025, it came in at $129.62 million, up 8.5% from FY2024.
- Research & Development has increased for six consecutive years, with a five-year compound annual growth rate of 30.8% (FY2020 to FY2025).
- By year, Research & Development came in at $119.48 million in FY2024 (+15.1%), $103.79 million in FY2023 (+21.1%), $85.73 million in FY2022 (+28.5%) and $66.69 million in FY2021 (+96.7%).
- The Q2 2026 figure ranks as the highest quarterly Research & Development in data going back to Q2 2017.
- Year over year, Research & Development gained in three of the last seven quarters, with growth averaging 11.7%.
- The high point for year-over-year Research & Development in five years was Q3 2021 (growth of 367.2%); the low point was Q4 2024 (a decline of 28.8%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | MeiraGTx Holdings | 1.05 Bn | 790.53 Mn | 314.27 Mn | 57.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 57.83 Mn |
| Dec 31, 2025 | 30.81 Mn |
| Sep 30, 2025 | 32.53 Mn |
| Jun 30, 2025 | 33.50 Mn |
| Mar 31, 2025 | 32.78 Mn |
| Dec 31, 2024 | 23.99 Mn |
| Sep 30, 2024 | 26.24 Mn |
| Jun 30, 2024 | 34.93 Mn |
| Mar 31, 2024 | 34.32 Mn |
| Dec 31, 2023 | 33.67 Mn |
| Sep 30, 2023 | 27.86 Mn |
| Jun 30, 2023 | 19.94 Mn |
| Mar 31, 2023 | 22.32 Mn |
| Dec 31, 2022 | 21.77 Mn |
| Sep 30, 2022 | 16.86 Mn |
| Jun 30, 2022 | 24.00 Mn |
| Mar 31, 2022 | 23.10 Mn |
| Dec 31, 2021 | 13.18 Mn |
| Sep 30, 2021 | 21.61 Mn |
| Jun 30, 2021 | 15.19 Mn |
API Access
MeiraGTx Holdings Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=MGTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "MGTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=MGTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();